Shares in Clearside Biomedical (NSDQ:CLSD) fell slightly today after the biopharmaceutical company missed earnings expectations on Wall Street with its second quarter results.
The Alpharetta, Ga.-based company posted a net loss of -$13.8 million on sales of $130,000 for the 3 months ended June 30, for bottom-line loss of -169% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical misses EPS estimate in Q2 appeared first on MassDevice.